Adverum Biotechnologies Inc
NASDAQ:ADVM

  • LAST PRICE
    7.6800
  • TODAY'S CHANGE (%)
    0.1400 (1.8568%)
  • Bid / Lots
    7.6800/ 2
  • Ask / Lots
    7.7000/ 2
  • Open / Previous Close
    7.5300 / 7.5400
  • Day Range
    7.2600
    7.7672
  • 52 Week Range
    6.3800
    29.7000
  • Volume
    74,888

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

  • Yesterday

      Show headlines and story abstract

    • 23 hours ago by MT Newswires
      Companies Mentioned: ADVM
      04:44 PM EST, 11/04/2024 (MT Newswires) -- ...

    • 23 hours ago by Dow Jones
      Companies Mentioned: ADVM

    • 23 hours ago by Dow Jones
      Companies Mentioned: ADVM

      E: ir@adverum.com
      Adverum Biotechnologies, Inc. Selected Consolidated Balance Sheet Data (In thousands) September 30 December 31 2024 2023 -------------- ------------- (Unaudited) (1) Cash and cash equivalents , and marketable securities $ 153,241 $ 96,526 Total assets 234,375 173,010 Total current liabilities 27,657 24,914 Total stockholders' equity 144,116 83,469 (1) Derived from Adverum's annual audited consolidated financial statements. Adverum Biotechnologies, Inc. Condensed Consolidated Statements of Operations (In thousands except per share data) Three months ended Nine months ended September 30, September 30, -------------------- ---------------------- 2024 2023 2024 2023 --------- --------- --------- ----------- (Unaudited) License revenue $ 1,000 $ - $ 1,000 $ 3,600 Operating expenses: Research and development 20,439 20,740 52,946 62,398 General and administrative 9,782 13,789 24,996 39,035 Total operating expenses 30,221 34,529 77,942 101,433 ------- ------- ------- ------- Operating loss (29,221) (34,529) (76,942) (97,833) Other income, net 2,087 1,661 6,545 4,437 ------- ------- ------- ------- Net loss before income taxes (27,134) (32,868) (70,397) (93,396) Income tax provision -- (17) -- (55) ------- ------- ------- ------- Net loss (27,134) (32,885) (70,397) (93,451) ------- ------- ------- ------- Net loss per share -- basic and diluted $ (1.30) $ (3.26) $ (3.63) $ (9.28) ======= ======= ======= ======= Weighted-average common shares outstanding - basic and diluted 20,876 10,100 19,408 10,069 ======= ======= ======= =======

  • Oct 16, 2024

      Show headlines and story abstract

    • 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
      Companies Mentioned: ADVM

      Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

      REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE(R) in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injection for the treatment of neovascular or wet age-related macular degeneration (wet AMD). Ixo-vec is currently being evaluated in the Phase 2 LUNA clinical trial. The company plans to announce LUNA 52-week data and pivotal program details in the 4(th) quarter of 2024. In addition, the company is on track to initiate the Ixo-vec pivotal program in the 1(st) half of 2025.

Peers Headlines